10 Jefferies Group Protagonist Therapeutics Trades
Jefferies Group's position in Protagonist Therapeutics is currently worth $33.9 Million. That's 0.62% of their equity portfolio (31st largest holding). The investor owns 1.03% of the outstanding Protagonist Therapeutics stock. The first Protagonist Therapeutics trade was made in Q4 2022. Since then Jefferies Group bought shares four more times and sold shares on five occasions. The stake costed the investor $15.8 Million, netting the investor a gain of 115% so far.
Avg closing price
Price range
Sold 57.6% shares (-858 Thousand shares)
Q1 2025
Avg closing price
$41.70
Price range
$35.09
-
$59.76
Sold 17.9% shares (-325 Thousand shares)
Q4 2024
Avg closing price
$43.53
Price range
$38.51
-
$48.43
Sold 11.1% shares (-226 Thousand shares)
Q3 2024
Avg closing price
$40.35
Price range
$33.72
-
$47.33
Increased shares by 72.8% (+860 Thousand shares)
Q2 2024
Avg closing price
$29.29
Price range
$24.66
-
$34.80
Sold 7.1% shares (-90 Thousand shares)
Q1 2024
Avg closing price
$27.21
Price range
$21.79
-
$32.15
Increased shares by 52.1% (+435 Thousand shares)
Q4 2023
Avg closing price
$17.50
Price range
$14.05
-
$23.44
Increased shares by 9.9% (+75 Thousand shares)
Q3 2023
Avg closing price
$19.40
Price range
$16.68
-
$23.66
New holding (+761 Thousand shares)
Q2 2023
Avg closing price
$25.03
Price range
$18.02
-
$29.36
Sold -100 Thousand shares
Q1 2023
Avg closing price
$16.79
Price range
$10.78
-
$25.38
New holding (+100 Thousand shares)
Q4 2022
Avg closing price
$8.44
Price range
$7.36
-
$11.17
